Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
ZO ZOM Zomedica Corp. FY ended Mar 16, 2026 | — | — | — | $32.03M | -$74.01M | -$81.86M | — | — | — |
AQ AQST Aquestive Therapeutics, Inc. FY ended Mar 02, 2026 | $5.02 | $630.07M | $760.34M | $44.55M | -$76.84M | -$83.78M | -6.44x | 14.14x | — |
AC ACAD ACADIA PHARMACEUTICALS INC FY ended Feb 18, 2026 | $29.11 | $5.02B | $5.09B | $1.07B | $150.66M | $391.00M | 12.66x | 4.68x | 33.81x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
AB ABBV AbbVie Inc. FY ended Feb 10, 2026 | $255.48 | $451.46B | $508.66B | $61.16B | $17.62B | $4.23B | 108.25x | 7.38x | 24.66x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 20.96x | 4/6 | -$832.68M | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 7.74x | 5/6 | $696.67K | $0.03 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 33.27x | 5/6 | -$1.32B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
ZO ZOM Zomedica Corp. FY ended Mar 16, 2026 | — | — | — | $32.03M | -$74.01M | -$81.86M | — | — | — |
AQ AQST Aquestive Therapeutics, Inc. FY ended Mar 02, 2026 | $5.02 | $630.07M | $760.34M | $44.55M | -$76.84M | -$83.78M | -6.44x | 14.14x | — |
AC ACAD ACADIA PHARMACEUTICALS INC FY ended Feb 18, 2026 | $29.11 | $5.02B | $5.09B | $1.07B | $150.66M | $391.00M | 12.66x | 4.68x | 33.81x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
AB ABBV AbbVie Inc. FY ended Feb 10, 2026 | $255.48 | $451.46B | $508.66B | $61.16B | $17.62B | $4.23B | 108.25x | 7.38x | 24.66x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 20.96x | 4/6 | -$832.68M | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 7.74x | 5/6 | $696.67K | $0.03 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 33.27x | 5/6 | -$1.32B | — | Target fundamentals do not produce a usable positive equity value. |
